CD274 and head and neck squamous cell carcinoma: In the phase IB KEYNOTE-012 trial, 60 patients with PD-L1 positive (>1%) R/M HNSCC (38% were HPV-positive and 62% were HPV-negative) were treated with pembrolizumab 10 mg/kg intravenously every two weeks [28].